Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2007 | Letter to the Editor

Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?

Authors: James C. Sisson, Anca M. Avram, Domenico Rubello, Milton D. Gross

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2007

Excerpt

Dear Sir, …

Allahabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA. Radiodiodine treatment of hyperthyroidism—prognostic factors for outcome. J Clin Endocrinol Metab 2001;86:3611–7.PubMedCrossRef

Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab 2003;88:978–83.PubMedCrossRef

Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Saimi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol 2004;61:641–8.CrossRef

Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves’ hyperthyroidism with radioioidine; results of a prospective study. Thyroid 1997;2:247–51.

Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy of Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 2002;29:1118–24.CrossRef

Alexander EK, Larsen PR. High dose ¹³¹I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 2002;87:1073–7.PubMedCrossRef

Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Brit Med J 1984;289:361–3.

IRCP. Protection of the patient in medicine. IRCP publication 52. Ann IRCP 1987;17 4:5. New York: Pergamon Press.

Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998;280:347–55.PubMedCrossRef

10.

Pollycove M, Feinendegen LE. Biologic responses to low doses of ionizing radiation: detrement versus hormesis. Part 2. Dose responses in organisms. J Nucl Med 2001;42:26N–37N.PubMed

11.

IRCP. Radiation dose to patients from radiopharmaceuticals. ICRP publication 53. Ann IRCP 1994;278. New York: Pergamon Press.

12.

Willemsen UF, Knewewitsch P, Kreisig T, Pickardt CR, Kirsch CM. Functional results of radioiodine therapy with 300-Gy absorbed dose in Graves’ disease. Eur J Nucl Med 1993;20:1051–5.PubMedCrossRef

13.

Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, et al. Calculation of the radioiodine dose for the treatment of Graves’ hyperthyroidism: is more than seven-thousand rad target dose necessary? Thyroid 1999;9:865–9.PubMed

14.

Lucas KJ. Use of ultrasound volume in calculating radioactive iodine dose in hyperthyroidism. Thyroid 2000;10:151–5.PubMedCrossRef

15.

Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated ¹³¹iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995;25:186–93.PubMedCrossRef

Title: Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?
Authors: James C. Sisson
Anca M. Avram
Domenico Rubello
Milton D. Gross
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0419-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2007

Brain reserve capacity in frontotemporal dementia: a voxel-based 18F-FDG PET study

The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?

Spatial dose distributions in solid tumors from 186Re transported by liposomes using HS radiochromic media

19th international IRIST congress 18 to 21 June 2008 Krakow, Poland

Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol

Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates